CODD RONALD E F
Known title: DirectorCIK: 0001201177
Associated companies
Transaction History
| VEEV | ▲ Buy | Option Exercise | 221 | $0 | 6/1/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 4,630 | $963K | 4/6/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 55 | $11K | 4/6/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 20,000 | $543K | 4/6/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 15,315 | $3.2M | 4/6/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 221 | $0 | 3/1/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 11,625 | $3.0M | 12/23/2021 | View on chart |
| VEEV | ▼ Sell | Other | 11,625 | $0 | 12/23/2021 | View on chart |
| VEEV | ▼ Sell | Gift | 6,000 | $0 | 12/16/2021 | View on chart |
| VEEV | ▼ Sell | Other | 6,000 | $0 | 12/16/2021 | View on chart |
| VEEV | ▼ Sell | Other | 11,500 | $0 | 12/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,582 | $692K | 12/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,717 | $733K | 12/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,775 | $752K | 12/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,407 | $376K | 12/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,019 | $543K | 12/13/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 221 | $0 | 12/1/2021 | View on chart |
| VEEV | ▼ Sell | Gift | 7,000 | $0 | 11/2/2021 | View on chart |
| VEEV | ▼ Sell | Other | 7,000 | $0 | 11/2/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 412 | $124K | 9/13/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 22,713 | $6.8M | 9/13/2021 | View on chart |
| VEEV | ▼ Sell | Other | 23,125 | $0 | 9/13/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 221 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.